Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer.

Author Affiliations

1: Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri. cynthiaxma@wustl.edu rbose@wustl.edu mjellis@bcm.edu.
2: Division of Public Health Science, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
3: Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
4: Department of Medicine, Stanford University School of Medicine, Stanford, California.
5: Department of Medicine, Duke Cancer Institute, Durham, North Carolina.
6: Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
7: Medical Oncology, Mayo Clinic, Rochester, Minnesota.
8: Medical Oncology, University of Southern California, Los Angeles, California.
9: Medical Oncology, Rush University Medical Center, Chicago, Illinois.
10: Department of Medicine, University of Alabama Birmingham, Birmingham, Alabama.
11: Department of Oncology-Hematology, St. Luke's Cancer Institute, Kansas City, Missouri.
12: Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.
13: Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
14: Guardant Health Inc., Redwood City, California.
15: Puma Biotechnology, Los Angeles, California.
16: Genomic and Pathology Service, Washington University School of Medicine, St. Louis, Missouri.
17: Department of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan.
18: Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
19: Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
20: Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas. cynthiaxma@wustl.edu rbose@wustl.edu mjellis@bcm.edu.